BERNARDSVILLE, N.J., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control mRNA translation, today announced the company will present at the Biotech Showcase™ 2019, taking place in San Francisco, CA, January 7 – 9, 2019.
Kevin Pong, Ph.D., vice president of business development of Anima Biotech, will provide an overview of the company’s business and technology during his presentation and will be available for questions and one-on-one meetings with attendees registered for the conference.
Details regarding the company’s presentation are as follows:
Event: Biotech Showcase 2019
Date: Tuesday, January 8, 2019
Time: 9:30 a.m. PT
Room: Franciscan D, Ballroom Level
Venue: Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA
About Anima Biotech
Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud based analysis software, we identify drug candidates that modulate a target protein’s production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit https://www.animabiotech.com
Media Contact:
Allison Blum, Ph.D.
LifeSci Public Relations
+1.646.627.8383
allison@lifescipublicrelations.com
